Cancer

Title
Study Using Two Investigational Drugs for Individuals with Breast Cancer who have Progressed while Receiving Prior Therapy
Trial Number
203459042011
Number of Participants
100
Principal Investigator

Shelly Lo

M.D., ABIM
Hematology/Oncology
Associate Professor
Eligibility

Patient must be female and at least 18 years old with HER2-positive, locally advanced or metastatic breast cancer who have previously received trastuzumab in any line of therapy, have received chemotherapy combined with HER2-targeted therapy for advanced disease, and have progressed while receiving their most recent therapy.

Purpose

The purpose of this study is to determine how safe and tolerable this combination of the two investigational drugs is in certain individuals with breast cancer. This extension study is designed to allow individuals who are benefitting from the combination to continue their treatment.

Enrollment

(708) 327-3154

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.